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G-protein coupled receptors (GPCRs) are found to be attractive drug targets for the treatment of various neuronal diseases. 
Allosteric modulators have their role in enhancing or suppressing the effect of glutamate on mGluRs. Structure of mGluR1 was 
generated with the help of Modeller software by considering human B2-adrenergic GPCR protein as template. Structure of various 
already known drug molecules were used for similarity search in the ZINC database and a large number of similar molecules were 
obtained, than filtering of these molecules were done by applying drug features. Molecules were screened by Molegro Virtual 
Docking program and numbers of novel molecules were generated by using LigBuilder software. Finally 16 novel drug candidates 
were selected, which were showing better results than the seed molecule and previously known modulators. These results will 
help in designing and synthesis of better drugs against diseases like Epilepsy and Parkinson’s. 
 
 





GPCRs are the large protein families that are found only in 
eukaryotes. They are the membrane spanning proteins that 
traverse the membrane several times [1]. There are a variety of 
ligands that can activate these receptors like hormones, 
pheromones, neurotransmitters and many others. GPCRs are 
now a day’s used as potent targets in the process of many 
modern drug developments. GPCRs play important role in 
causing many diseases like neuronal dysfunction including 
seizures, Parkinson’s disease, night blindness and epilepsy [2]. 
Antagonists of mGluRs may exert anticonvulsant effect in 
contrast to soman-induced seizures in rats challenged with 
soman  [3]. Glutamate plays a very crucial role of excitatory 
neurotransmitter in brain. mGluRs are a member of GPCR 
super family. Metabotropic receptors are a type of GPCRs as 
their activity involves in a series of intracellular events which 
involves the activation of G-protein and often signal 
transduction pathway. Glutamate which is an amino acid acts 
as a neurotransmitter [4]. Swanson C. J. et al indicated that 
mGluR are interesting new targets to treat human’s anxiety and 
stress disorders [5]. Among known eight classes of mGluRs the 
most extensively studied receptor is the metabotropic glutamate 
receptor mGluR1 because of their pharmacological, 
physiological, and anatomical as well as biochemical 
characteristics [1]. There are two states of GPCR proteins i.e. 
active state and inactive states, and these states maintains 
equilibrium with each other and can switch over to each other 
on sensitization of any ligand or external signals[1]. Active 
structure of mGluR1 was modeled by using human B2-
adrenergic G protein-coupled receptor as template [6]. 
 
Materials and Methods: 
Obtaining template sequence from PDB 
mGluR proteins previously used the structure of Rhodopsin 
protein as a template to model the structure of other GPCRs as 
stated by Melherbe et al [4]. In this work human B2-adrenergic BIOINFORMATION  open access 
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G protein-coupled receptor protein was selected as template 
strand because it has similar active sites and activation 
mechanism of mGluR protein [6]. The structure of human B2-
adrenergic G protein-coupled receptor was taken from PDB 
database having the PDB ID 2RH1 in the activated state and the 
structure was generated for mGlur1 its sequence was obtained 
from NCBI,GenBank [7, 8]. 
 
Modelling and Evaluation 
Homology model of mGlur1 protein was generated by using 
Modeller 9v7 version and finally structures were evaluated by 
using Procheck program [9, 10]. 
 
Similarity searching on ZINC database 
ZINC database was used to obtain similar molecules on the 
basis of the structures of previously known ligands, similar 
molecules screened based on drug likeliness parameters and 
also based on Lipinski’s rule of 5 [11]. 
 
Pharmacophore generation 
The pharmacophore structure was generated by extracting the 
information about the common interacting atoms among 15 
already known ligand molecules with the help of Pharmagist 
online server [12, 13]. 
 
Docking and interaction study 
The Molegro docking program was used for analyzing the 
binding between receptor and ligand molecules to study the 
existing interaction between the receptor and the ligand 
molecule Ligplot was used [14, 15]. 
 
 
Figure 2: Showing the basis of preparing the seed  
Designing Novel drug like molecules 
The de novo method of ligand designing process was done 
using the Ligbuilder software (Figure 2) in which Pocket, Grow 
and Process modules have been used to develop novel drug 
candidates [16, 17]. 
 
Results  
The Ramachandran plot in case of active mGluR1 protein was 
showing that 90.5% residues were falling in the core region, 
8.8% of the total residues in the allowed region and 0.7% in the 
generously allowed region. By analyzing Naveena et al., 2008 
work allosteric modulators were used and developed 
pharmacophore (Figure 3), based on this pharmacophore Zinc 
database has been screened (Figure 1) and finally 200 molecules 
obtained [1].  
 
 
Figure 1: Showing the docked position of ligand (ID- 
ZINC24890) in the cavity in two different forms.  
 
On the basis of docking energies 12 molecules were selected. In 
the other method de novo ligand designing done and results 
into 200 novel molecules, from this finally 16 potent molecules 
were screened based on binding energies and other parameters 
Table 3 (see supplementary material). After docking the 
molecules obtained by de novo and similarity search method 
both are showing better results than the previously known drug 
molecules Table 2a & 2b (see supplementary material).Total 
energy of 10 best ligands obtained by both de novo method and 
similarity search method were compared (Figure 4), it shows 
ligands generated by de novo designing method have greater 
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Figure 4: Comparison of the energy values between ligands 
generated by de novo method and ligands obtained by 
similarity search method by pharmacophore based on ZINC 
database. 
 
The total energy value of the pivot molecule was found to be -
132.576; it has been compared by the ligands generated by the 
de novo method. The graph shows that (Figure 5) the energy 
comparison of the drug like molecules generated by LigBuilder 
and the energy of pivot molecule (Figure 6) i.e. -132.576, it is 
observed the de novo method based developed ligands are 
better than the pivot molecule. The residues involved in the 
close interaction (Glycine 120, Alanine 117, Methionine 207 and 
Methionine 86 while the residues that are distantly interacted 
with the ligands are Asp 83, Lys 296, Ala 83, Thr 118 and Ala 
169) were obtained by Ligplot analysis and a pivot molecule 
(ZINC ID: [00] ZINC24890) was selected based on 
pharmacophoric characters. A graph has been generated by 
comparing the energy values of 10 best previously known 
ligands and the ligands generated by de novo method.  
 
 
Figure 5: Comparison of the energy values between ligands 
generated by de novo method and the pivot molecule (ZINC 
ID: [00]  ZINC24890). 
 
Figure 6: Comparison of the energy values between ligands 
generated by de novo method and the pivot molecule. Series 
one indicates energy of molecule generated by de novo and 
series two indicates energy of molecule generated by pivote 
molecule. The blue color represents the de novo ligands while 
red one indicates already known ligands. 
 
Discussion:     
Our goal was to generate suitable drug candidate which can be 
used for the treatment of neural dysfunction diseases. We got 
insight from previous work of Melherbe et al  [4] who used 
structure of Rhodopsin protein as a template to model the 
structure of other GPCRs. Human B2-adrenergic GPCR 
template because it has similar active sites and activation 
mechanism of mGluR protein [6]. Human B2-adrenergic G 
protein-coupled receptor structure was taken from PDB in the 
activated state and the structure was generated for mGlur1 [7, 
8]. Homology model of mGlur1 protein was generated and 
finally structures were evaluated [9, 10]. ZINC database was 
used to obtain similar molecules on the basis of the structures of 
previously known ligands, similar molecules screened based on 
drug likeliness parameters and also based on Lipinski’s rule of 5 
[11]. Pharmacophore structure was generated by extracting the 
information about the common interacting atoms among 15 
already known ligand molecules [12, 13]. Analyzed the binding 
between receptor and ligand molecule [14].The de novo method 
of ligand designing process was also performed to develop 
novel drug candidates [16]. It was found de novo based drugs 
showed better binding than pivot molecule. 
 
Conclusion: 
However the ligands generated through our method are 
showing better binding to mGluR glutamate receptor protein as 
compared to previous work. Hence they may be better 
modulators for the activity of mGluR1 protein. They may help 
to treat various neural dysfunctions like Epilepsy and 
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Table 1: Comparison of various parameters of ligand molecules obtained by Pharmacophore based similarity searching using ZINC database. 
ZINC ID  M. Wt. 
(dalton) 
        Total 
Energy(KJ/mol) 





ID -[00]ZINC1025445  372.421  -151.029  -0.0206  3.61  -116.398 
ID-[01]ZINC1025451 371.421  -158.326  -0.339  3.61  -120.465 
ID-[02]ZINC5553120 292.296  -117.324  -8.003  0.01  -101.15 
ID-[03]ZINC636503 355.349  -132.789  -2.232  4.50  -113.391 
ID-[04]ZINC753995 355.349  -134.974  -1.350  4.15  -108.543 
ID-[05]ZINC856324 415.401  -153.856  -1.170  4.21  -126.366 
ID-[06]ZINC856325 415.405  -152.931  -3.062  4.16  -122.806 
ID- [07]ZINC856326  443.455  -175.99  -2.17  4.96  -33.027 
ID-[08]ZINC2478323 387.347  -148.81  -5.322  3.14  -24.577 
ID-[09]ZINC4217469 450.69 -63.444  -0.2227  4.08  -88.974 
ID-[010]ZINC24890 322.409  -32.576  -1.086  3.42  -100.85 
ID- [011]ZINC1542199  351.471  -41.799  -2.670  4.05  -11.568 
 
Table 2(a) and 2(b): Previously known ligands and their docking energy (KJ/mol) values used to develop analogues [2]. 
Ligands  AMN082 PTEB  CPPHA Fenobam Ro01-6128 Ro67-7476 Ro67-4853 CPCCOEt 
Energy  value  -145.879  -142.98  -139.9 -133.78 -129.165 -129.091 -126.491 -126.052 
 
Table 2(b) 
Ligands  SIB-1757 SIB-1893 MTEP  5MPEP MPEP  MPEP-gamma PHCCC 
Energy value  -103.186 -102.282 -102.314  -101.01 -99.897  -96.861  -105.279 
 
Table 3: Comparison of various parameters of the drug analogues obtained by de novo method and their IUPAC names (by Marvin sketch). 
        ID   
of molecules 
                     IUPAC name of molecules      M. Wt.    
(Dalton) 
        Total                
Energy(KJ/mol) 









387.6 159.827  -5.1906  4.75  -57.807 
ID- result_002  (4S,6S,8E,12E,14E)-8-(1-carbamoyleth-1-en-1-yl)-4-[ethane-1,2-bis(ylium)-1-
yl]-6-hydroxy-14-(prop-3-en-1-ylidene)heptadeca-8,11,12-triene-1,2,3,9,17-
pentakis(ylium) 
387.5 -164.761  -5.26  4.76  -71.44 
ID- result_003  (6R)-1-(ethan-2-ylium-1-yl)-2-[(1E,5E,8S)-8-hydroxy-6-[1-
(methylcarbamoyl)eth-1-en-1-yl]dodeca-1,2,5-triene-5,11,12-tris(ylium)-1-
yl]-4-methylidene-6-methyliumylcyclohex-2-en-1-ide 
399.6 -169.566  -6.456  4.41  -40.10 
ID- result_004  (5S,7E,11E,13E)-5-hydroxy-7-[1-(methylcarbamoyl)eth-1-en-1-yl]-13-(prop-2-
en-1-ylidene)hexadeca-7,10,11-triene-1,2,8,16-tetrakis(ylium) 
359.5 -156.661  -2.32  4.73  -121.532 
ID- result_005  (4E,5E)-9-[(1E,2S,5R)-2-[(1Z)-buta-1,3-dien-1-ylium-1-yl]-5-[2-
(carbamoylamino)-2-oxoethyl]cyclohexan-4-ylium-1-ylidene]-4-(prop-2-en-
1-ylidene)nona-5,6-diene-1,9-bis(ylium) 
396.6 -158.947  -0.557  4.70  -14.94 
ID- result_006  (3E,7E,9E)-3-[(2R,4R)-2,4-dihydroxyhexyl]-9-(prop-2-en-1-ylidene)dodeca-
1,3,6,7-tetraene-1,4,12-tris(ylium) 
318.5 -156.896  -7.59  4.50  -107.004 
ID- result_007  (5S,7E,11E,13E)-7-(1-carbamoyleth-1-en-1-yl)-5-hydroxy-13-(prop-2-en-1-
ylidene)hexadeca-7,10,11-triene-1,2,8,16-tetrakis(ylium) 
445.5 -153.66  -0.73  4.33  -54.69 
ID- result_008  [(3E,5E,9E,14R,15E)-14-(2-oxoethyl)-4-(propan-3-ylium-1-yl)heptadeca-
3,5,6,9,15-pentaene-9,10,12,15,16,17-exakis(ylium)-1-yl]urea 
374.6 -165.401  -3.66  4.23  -130.615 
ID- result_009  [(3E,5E,9E,14R,15E)-14-(2-oxoethyl)-4-(propan-3-ylium-1-yl)heptadeca-
3,5,6,9,14-pentaene-9,10,12,15,16,17-hexakis(ylium)-1-yl]urea 
374.6 -170.744  -4.833  4.32  -140.22 
ID- result_010  (4E,6E,10E,12R,17R)-12-ethenyl-17,19-dihydroxy-6-methyl-13-oxo-5-
(propan-3-ylium-1-yl)nonadeca-4,6,7,10-tetraene-1,10-bis(ylium) 
392.6 -156.275  -9.49  4.56  -104.845 
ID- result_016  (4E,5E,9E,11S)-12-[(4R)-4-hydroxycyclohex-1-en-2-ylium-1-yl]-11-(2-
hydroxyethyl)-4-(3-oxopropylidene)trideca-5,6,9,12-tetraene-1,9,10-
tris(ylium) 
372.5 -186.026  -5.73  4.98  -110.593 
ID- result_025  [(3E,5E,9E,14R,15E)-14-(2-oxoethyl)-4-(propan-3-ylium-1-yl)heptadeca-
3,5,6,9,15-pentaene-9,10,12,15,17-pentakis(ylium)-1-yl]urea 
374.6 -162.96  -3.348  4.32  -85.30 
ID- result_056  (4E,6E,9E)-10-[(3S)-3-[(1S)-1,2-dicarboxyethyl]cyclopent-1-ene-2,4-
bis(ylium)-1-yl]-5-(propan-3-ylium-1-yl)deca-1,4,6,8,9-pentaene-1,2,7-
tris(ylium) 
358.5 -165.279  -7.744  4.32  -104.75 
ID- result_078  (4E,6E,9E)-10-[(3S)-3-[(1R)-1-carboxy-2-hydroxyethyl]cyclopent-1-ene-2,4-
bis(ylium)-1-yl]-5-(propan-3-ylium-1-yl)deca-1,4,6,8,9-pentaene-1,2,7-
tris(ylium) 
330.5 -161.192  -5.190  5.01  -108.786 
ID- result_101  [(3R,4E,6S,10E,12E)-11-methyl-6-(2-methylprop-2-en-1-yl)-12-(3-
oxopropylidene)pentadeca-4,9,10-triene-1,7,15-tris(ylium)-3-yl]urea 
388.6 -162.623  -2.74  4.05  -85.424 
ID- result_089  (4E,6E,9E)-10-[(3S)-3-[(1R)-1-carboxy-2-hydroxyethyl]cyclopent-1-ene-2,4-
bis(ylium)-1-yl]-5-(propan-3-ylium-1-yl)deca-1,4,6,8,9-pentaene-1,2,7-
tris(ylium) 
320.5 -159.478  -4.24  4.95  -93.99 
 
 